Furthermore, Yamamoto et al. [39] identified a role of ARID2 in multiple myeloma, the expression of this molecule, which may be associated with the prognosis of the disease and may be an effective therapeutic target for patients with lenalidomide-resistant multiple myeloma. This evidence concerns the gene ARID2 and plasma cell myeloma.